Company intelligence / Profile preview

Ningbo Tai Kang Medical Technology

Ningbo, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Company holds exclusive global rights from AstraZeneca for AZD3229, a small molecule KIT/PDGFRα inhibitor in development for GIST. Clinical data not disclosed publicly; preclinical data reportedly show efficacy and favorable safety.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

AstraZeneca (global licensing of AZD3229)

Beyond the preview

Go deeper on Ningbo Tai Kang Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningbo Tai Kang Medical Technology.

Explore the full profile